Immunotherapy after chemoradiation for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new drug called zimberelimab, which helps the immune system fight cancer, after standard radiation and chemotherapy for cervical cancer. It might improve the chances of keeping the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a certain type of cervical cancer, confirmed by a biopsy.
- Your cancer is locally advanced, meaning it hasn't spread far but is large or has grown into nearby tissues.
- You are between the ages of 18 and 70.
- You are physically able to care for yourself (fully active or light activity only).
- You have not had immunotherapy before.
- You are willing to use birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a tailored “extra” treatment after surgery—guided by a lab test called minimal residual disease (MRD)—can reduce the risk of cervical cancer coming back. It focuses on people with certain stages of cervical cancer who can follow the treatment plan and study follow-up.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
This trial is testing a new immunotherapy drug (adebrelimab) given along with standard chemoradiation for advanced cervical cancer. The goal is to see if adding this drug improves treatment effectiveness.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) alongside radiation therapy for people whose cervical cancer has returned or spread to a few other places. The goal is to see if this approach can help control the cancer better and improve survival.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.